| 产品名称: | Cryptococcus neoformans (Sanfelice) Vuillemin |
|---|---|
| 商品货号: | TS156895 |
| Deposited As: | Cryptococcus neoformans (Sanfelice) Vuillemin, anamorph |
| Strain Designations: | MCC1 |
| Alternate State: | Filobasidiella neoformans Kwon-Chung |
| Biosafety Level: | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format: | frozen |
| Storage Conditions: | Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section |
| Type Strain: | no |
| Antigenic Properties: | serotype A, serotype A
Ref![]() Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150 |
| Preceptrol®: | no |
| Medium: | ATCC® Medium 1245: YEPD |
| Growth Conditions: | Temperature: 30.0°C |
| Name of Depositor: | J Heitman |
| Special Collection: | NCRR Contract |
| Isolation: | derived from M049 by disrupting the FRR1 gene |
| References: | Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150 Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150 |

Cruz MC, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19: 4101-4112, 1999. PubMed: 10330150